HB 111 Pennsylvania House · 2025-2026 Regular Session

An Act prohibiting discrimination in certain life insurance policies based on certain drugs.

HB 111 prohibits life insurance companies in Pennsylvania from denying coverage, limiting benefits, or charging higher rates to applicants or policyholders solely because they have been prescribed an opioid overdose reversal agent (like naloxone). The bill directly affects individuals who use these medications, including those with opioid use disorder or at risk of overdose. It defines "adverse action" to include these discriminatory practices and makes such actions violations of existing laws against unfair insurance practices. The law takes effect 60 days after enactment.
Bill status passed 3 of 5 stages cleared
Introduction
Jan 2025
Committee Review
Mar 2025
House Passage
Mar 2025
Senate Passage
Governor
Introduced Jan 14, 2025 Last action Mar 17, 2025
Floor votes · House Mar 17, 2025

How they voted

15349
Passed
Total votes 202
Mar 17, 2025
D Democratic101
101 Yea
100% Yea
R Republican101
52 Yea 49 Nay
51% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
10
Key actions
3
Committee
5
Mar 17, 2025
Committee
Referred to Banking & Insurance
upper
Mar 17, 2025
Lower · Passed
Third consideration and final passage
lower
Mar 17, 2025
Lower · Passed
Re-reported as committed
lower
Feb 5, 2025
Committee
Re-committed to Appropriations
lower
Jan 29, 2025
Lower · Passed
Reported as committed
lower
Jan 14, 2025
Committee
Referred to Insurance
lower
1 primary · 21 co-sponsors

Sponsors